In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting.


Çakir H., EROĞLU O.

Iranian journal of basic medical sciences, vol.24, no.11, pp.1515-1522, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 11
  • Publication Date: 2021
  • Doi Number: 10.22038/ijbms.2021.58393.12971
  • Journal Name: Iranian journal of basic medical sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Index Islamicus, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.1515-1522
  • Keywords: Apoptosis Breast neoplasms Drug synergism Capecitabine Histone deacetylase - inhibitors
  • Bilecik Şeyh Edebali University Affiliated: Yes

Abstract

© 2021 Mashhad University of Medical Sciences. All rights reserved.Objective(s): Mouse breast cancer cell line 4T1 can accurately mimic the response to immune receptors and targeting therapeutic agents. Combined therapy has emerged as an important strategy with reduced side effects and maximum therapeutic effect. Mocetinostat (MGCD0103) is one of the members of Class I Histone Deacetylase Inhibitors (HDACi) and its mechanism of action has not been defined, yet. Capecitabine (Xeloda) is an antimetabolite and currently is widely utilized to treat a wide range of solid tumors. The aim of this study was to investigate the effects of the capecitabine, mocetinostat and their combined application on the 4T1 cell line. Materials and Methods: The effects of combined administration of mocetinostat and capecitabine on 4T1 cells were investigated by cell viability and migration assays, apoptosis analysis, and Western blotting technique. Results: The concentrations of drugs that give a half-maximal response (IC50) were detected for capecitabine (1700 μM), mocetinostat (3,125 μM), and 50 μM Capecitabine+1,5 μM Mocetinostat for 48 hr. In capecitabine+mocetinostat combine group, we observed that cell migration decreased, DNA fragmentation increased compared to the control group. capecitabine + mocetinostat group induced apoptosis by decreasing Bcl-2, PI3K, Akt, c-myc protein levels, while increasing Bax, Caspase-3, PTEN, cleaved-PARP, Caspase-7, Caspase-9, p53, cleaved-Cas-9 protein levels in 4T1 cells. Conclusion: Capecitabine and mocetinostat played a toxic role through inducing apoptosis on 4T1 cancer cells in a time- and concentration-dependent manner. These results showed that combined therapy with low concentrations were detected to be more effective than that with high-concentration alone drug treatment.